Kyntra Bio
KYNB
152 hedge funds and large institutions have $208M invested in Kyntra Bio in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 55 increasing their positions, 47 reducing their positions, and 49 closing their positions.
90% more call options, than puts
Call options by funds: $28.1M | Put options by funds: $14.8M
17% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 47
0.11% less ownership
Funds ownership: 3.24% → 3.13% (-0.11%)
11% less funds holding
Funds holding: 171 → 152 (-19)
39% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 49
85% less capital invested
Capital invested by funds: $1.42B → $208M (-$1.22B)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$46.5M |
| 2 |
AC
Armistice Capital
New York
|
+$33.8M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$30.6M |
| 4 |
BlackRock
New York
|
+$27.6M |
| 5 |
Jane Street
New York
|
+$27.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$56.7M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$39.7M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$25.2M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$17.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.9M |
KYNB Hedge Fund Activity: Q2 2023 in Review
152 institutional investors reported a position in Kyntra Bio (KYNB) for Q2 2023, worth a combined $208M — down 85% from $1.42B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of KYNB and 30 opened new positions — a net loss of 19 holders — while 47 trimmed existing stakes and 55 added.
The largest buyer was Millennium Management, adding an estimated $46.5M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $56.7M sold.
- 152 institutional investors held Kyntra Bio (KYNB) as of Q2 2023, down from 171 in Q1 2023.
- Funds reported $208M of Kyntra Bio stock for Q2 2023, down 85% quarter-over-quarter.
- 30 funds opened new Kyntra Bio positions in Q2 2023 and 49 closed out, a net change of -19 holders.
- The largest Kyntra Bio buyer in Q2 2023 was Millennium Management, an estimated $46.5M added.
- The largest Kyntra Bio seller in Q2 2023 was Point72 Asset Management, an estimated $56.7M sold.
Based on aggregated 13F filings for Q2 2023.